Boston, USA. State-of-the-art developments in laboratory automation and robotics were reflected in the symposium programme, which included papers and posters on all aspects of the technology--drug discovery research, data handling and data management, chemical analysis, re-engineering the laboratory, laboratory workstations, bioanalytical assays, managing laboratory automation, dissolution testing, pharmaceutical analysis, automation and combinatorial chemistry, validating automated methods and advanced topics. We are printing abstracts of papers from ISLAR and we hope that you find them informative and productive. Abstracts of papers presented at the 1997 ISLAR objectives of the study were to understand the future direction of the discovery research process, analysing the impact of new technology, the implications for process organization and management, and the goals that cutting-edge discovery companies are setting themselves for the future. A broad survey was undertaken of discovery companies, with a representative sample of ten companies ranging from the top-tier pharmaceutical majors, through middle and lower tier players to biopharmaceu-
The pharmaceutical industry needs to not only discover new molecules but also to develop them as efficiently and effectively as possible. Success is being first to market, not necessarily first to proof of concept. To be successful, development needs to reduce timelines while maintaining quality and preventing burnout. While automation obviously plays a very significant role in this approach, many other factors must be in place for automation to be as effective as possible. These factors include planning, process optimization, organizational structure, people development and the need to see the total picture. This presentation discussed these factors and their relationship with automation. It evaluated less obvious areas of automation, like document management, as well as the more established ones and discussed the premise, that it is the integration of all these aspects, including automation, that truly offers the biggest opportunities.
Re-inventing drug discovery: issues and actions in the quest for innovation and productivity Pradip Banerjee, Andersen Consulting, Florham Park, 2VJ, USA As it approaches the 21st century, the pharmaceutical industry has re-emphasized its focus on innovative drug discovery as the key to future success. Prioritizing innovation has become a strategic imperative in an increasingly competitive environment, and the hurdles for success are extremely high. In order to sustain revenue growths at the 10% level that the industry has historically produced, the major global pharmaceutical players must average between 5-6 significant (that is, with a sales potential of greater than $350M/year) NCE launches annually in the future. Andersen Consulting has conducted a study of how pharmaceutical companies must restructure their drug discovery programmes to develop the high performance drug discovery processes necessary for future success. The 0142-0453/98 $12.00 (C) 1998 Taylor & Francis Ltd objectives of the study were to understand the future direction of the discovery research process, analysing the impact of new technology, the implications for process organization and management, and the goals that cutting-edge discovery companies are setting themselves for the future. A broad survey was undertaken of discovery companies, with a representative sample of ten companies ranging from the top-tier pharmaceutical majors, through middle and lower tier players to biopharmaceutical companies, in the US, Europe, and Japan. One hundred interviewees covered all aspects of involvement with the discovery process, among them senior management of the R&D function and therapeutic areas, and individuals in biological, chemical, development and IT functions.
The Andersen Consulting study highlights the intimidating scale of the task facing discovery companies. In order to maintain the goals set to maintain market competitiveness, more NCE candidates for clinical development must be produced, and faster. New goals set by companies surveyed are a minimum of one NCE per 100 discovery research staff, and a doubling of the speed of delivery of NCEs to clinical development, from up to seven years to less than three. Quality must not be compromised by quantity; company goals are more development-ready compounds to lower the attrition rate of clinical development, and, ultimately, to ensure that the launch of truly innovative products to reap maximum reward on investment.
The effective exploitation of the new technologies transforming the drug discovery process will be a key to meeting these goals. It is clear from Andersen Consulting research that the key to high performance drug discovery is as much about the development of effective processes, information management, and people organization as it is about new technologies. Andersen Consulting has developed recommendations for an approach to high performance drug discovery which optimizes the interaction of these elements.
Effective co-ordination of technology, process and people will require an IT integration strategy which optimizes the potential of all three. Knowledge, rather than information management must be the key goal, with comprehensive and integrated applications to support the whole process from target generation and characterization, lead identification and optimization, and the discovery/development interface. Since it is often the case that the projects with the greatest potential rewards have the lowest probability of success, it is not surprising that priorities among projects can change dramatically and quickly. HTS groups are frequently evaluated by numerical measures of productivity, such as samples tested per week and number of screens completed per year. Naturally, this emphasis on throughput encourages the HTS group to prioritize in favour of screen designs which are easier to implement and run. Although in many cases conversion of assays into preferred screen formats will improve efficiency, some molecular targets may be deprioritized because they will decrease the perceived productivity of the HTS group.
Progress in developing new technologies and a commitment to development of the people within the HTS organization are two other factors which must also influence the setting of priorities. Evaluating and introducing new technologies--hardware, software, assay formats--is time consuming and reduces productivity in the short term. When successful, however, the results may be improved productivity or the ability to perform screens previously deprioritized for being too difficult.
People development must be a major concern, because it is the people who develop and implement the new technologies and determine how productive the robotics and automated equipment will actually be. HTS is most successful meeting the priorities for drug discovery research through the ability of the people in the HTS group to understand the needs of investigators on a variety of drug discovery projects, and the progress derived from the new technologies and to achieve the highest level of productivity possible.
Planning and establishment of a high throughput screening site Julie j. Tomlinson, Brent T. Butler Even so, laboratory robotics had and still has problems. HTS assays were simplified and reduced to pipet and quantitate assays whenever possible. These homogeneous assays are highly dependent on the robotic pipetting device and on the quantitation device. The throughput is determined by how rapidly these steps are performed. Robotic pipettors have evolved to at least 8-tip instruments with 96-tip pipettors gaining a major foothold in HTS laboratories. The robotic pipettors are truly the heart of the HTS effort. In some cases, it has become necessary to have the pipettor built within the machine such as with FLIPR which is a fluorescent imaging system for whole cell assays. These specialized 'workstation' type devices need to be available within the HTS laboratory since a wide variety of cellular and molecular assays make up the assay profile in HTS.
The more recent push to generate even larger libraries through combinatorial chemistry has again set higher throughput demands. The future may well be UHTS which will require new robotic concepts to meet the demands for robustness of these systems. Clearly, the days of a single robot running up and down a single track will soon and robust assay for PGE2 (an indicator of kidney PG metabolism) and 6-keto-PGFl (an indicator of prostacyclin production), from human urine. The lower limit of quantitation for both the analytes is 10 pg/ml using ml human urine. The method involves elaborate extraction and derivatization steps. A Zymark-RapidTrace SPE 
